Copertina

Nutrition and behavioral health in cystic fibrosis: Eating and body image

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Emma R. Lyons, Emily Muther, Sabina Sabharwal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Pediatric Pulmonology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis
di: Emma R. Lyons, et al.
Pubblicazione: (2025)

Prevalence of cannabidiol use in persons with cystic fibrosis
di: Emma M. Tillman, et al.
Pubblicazione: (2024)

The foregut in cystic fibrosis
di: Christopher Vélez, et al.
Pubblicazione: (2024)

Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
di: Cameron J. McKinzie, et al.
Pubblicazione: (2024)

Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis
di: CM. López Cárdenes, et al.
Pubblicazione: (2024)

Time to be blunt: Substance use in cystic fibrosis
di: Sanaz Vaziri, et al.
Pubblicazione: (2024)

The future of cystic fibrosis: A global perspective
di: Felix Ratjen
Pubblicazione: (2024)

Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
di: Hiep Pham, et al.
Pubblicazione: (2024)

Clinical evidence of pancreatic recovery in children with cystic fibrosis on ivacaftor
di: Sydney Walker, et al.
Pubblicazione: (2024)

Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
di: Kamyron Jordan, et al.
Pubblicazione: (2024)

Predicting weight gain in patients with cystic fibrosis on triple combination modulator
di: Kelly L. Stewart, et al.
Pubblicazione: (2024)

Codevelopment of a model of care for adults living with cystic fibrosis‐related diabetes
di: Shanal Kumar, et al.
Pubblicazione: (2024)

The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis
di: Nicole Green, et al.
Pubblicazione: (2024)

Me, myself, and I: A systematic review of cystic fibrosis and self‐concept
di: Maggie Harrigan, et al.
Pubblicazione: (2024)

Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis
di: Anna M. Georgiopoulos, et al.
Pubblicazione: (2024)

Lung T1 MRI assessments in children with mild cystic fibrosis lung disease
di: Clement L. Ren, et al.
Pubblicazione: (2024)

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche
di: Gizem Tamer, et al.
Pubblicazione: (2024)

Overnutrition in persons with cystic fibrosis on modulator therapy and the relationship to obstructive sleep apnea
di: Aesha M. Jobanputra, et al.
Pubblicazione: (2024)

Improving implementation and team communication by integrating a cystic fibrosis transition readiness (CF R.I.S.E.) program into electronic health records
di: Catherine Enochs, et al.
Pubblicazione: (2024)

Evaluation of otorhinolaryngologic, audiologic, and genetic findings in children with cystic fibrosis: A tertiary care experience
di: Halime Nayır Büyükşahin, et al.
Pubblicazione: (2024)

Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study
di: Megan Poulsen, et al.
Pubblicazione: (2024)

A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor
di: Nora Burdis, et al.
Pubblicazione: (2024)

Successful treatment of Stenotrophomonas maltophilia with ceftazidime‐avibactam and aztreonam in an individual with cystic fibrosis: A case report
di: Stephanie Duehlmeyer, et al.
Pubblicazione: (2024)

Comparison of particles in exhaled air and multiple breath washout for assessment of small airway function in children with cystic fibrosis
di: Annelies M. Zwitserloot, et al.
Pubblicazione: (2024)

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
di: Shanal Kumar, et al.
Pubblicazione: (2024)

Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
di: Nagehan Emiralioğlu, et al.
Pubblicazione: (2024)

Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy
di: Brenda M. Morrow, et al.
Pubblicazione: (2024)

Nebulized granulocyte macrophage‐colony stimulating factor to stabilize lung function in nontuberculous mycobacteria pulmonary disease in cystic fibrosis
di: Colette Biro, et al.
Pubblicazione: (2024)

The rebound effect: Reoccurrence of nasal polyps following discontinuation of a CFTR modulator in a patient with cystic fibrosis sinus disease
di: Brittany A. Wright, et al.
Pubblicazione: (2024)

Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome
di: Brian J. Carroll, et al.
Pubblicazione: (2024)

A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis
di: Sabrina J. Sherwood, et al.
Pubblicazione: (2024)

Implementation and outcomes of a quality improvement project to systematically assess the gross motor skills in school‐aged children with cystic fibrosis
di: Abby Good, et al.
Pubblicazione: (2024)

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
di: Valeria Daccò, et al.
Pubblicazione: (2024)

“I eat chocolate milk for dinner because we just have nothing in our fridge”: The invisible burden and dire consequences of food insecurity for people with cystic fibrosis in the United States
di: Soumya J. Niranjan, et al.
Pubblicazione: (2024)

New York cystic fibrosis consortium newborn screening quality improvement: Development and implementation of a statewide consensus recommendations for management of infants with CFTR‐related metabolic syndrome
di: Saroj Choudhary, et al.
Pubblicazione: (2024)

A rare variant c.1802T>C (p. Ile601Thr) associated with severe phenotype among people with cystic fibrosis from south India, and potential genetic admixture in Réunion, France
di: Madhan Kumar, et al.
Pubblicazione: (2024)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
di: Don S. Urquhart, et al.
Pubblicazione: (2024)

Cystic fibrosis year in review 2023
di: David V. Swetland, et al.
Pubblicazione: (2024)

Cystic fibrosis in Iceland and the high prevalence of the N1303K variant
di: Helga Elidottir, et al.
Pubblicazione: (2024)

Infection and Inflammation in the Cystic fibrosis (CF) airway
di: Malena Cohen‐Cymberknoh
Pubblicazione: (2024)